US Edition
Weight loss and diabetes jabs linked to potentially fatal side effect
UNITED KINGDOM, JUN 26 – The UK study targets genetic factors in hundreds of pancreatitis cases linked to GLP-1 drugs, with over 560 reports including six fatalities, to improve personalized patient safety.
- The UK MHRA reported over 560 suspected pancreatitis cases linked to GLP-1 drugs, including Mounjaro, Wegovy, and Ozempic, with several deaths.
- This follows wider adoption of GLP-1 agonists, prescribed for type 2 diabetes and weight management, used by approximately 1.5 million people in the UK.
- Reported cases include 181 linked to tirzepatide in Mounjaro with five deaths, 116 linked to liraglutide with one death, 113 linked to semaglutide in Wegovy and Ozempic with one death, and 101 linked to exenatide with three deaths.
- MHRA and Genomics England launched the Yellow Card Biobank to investigate potential genetic factors increasing pancreatitis risk, aiming to enable safer, personalized treatments.
- The MHRA urges patients hospitalised with acute pancreatitis on GLP-1 drugs to report via the Yellow Card scheme, which supports research expected to improve patient safety and reduce NHS costs.
134 Articles
134 Articles
UK investigates weight-loss jab risks after many hospitalised with pancreatitis
The UK’s MHRA and Genomics England have launched a groundbreaking study to investigate whether genetics play a role in developing acute pancreatitis after taking GLP-1 weight-loss drugs like Ozempic, Mounjaro, and Wegovy.
It doesn't matter how many extra pounds you have, the drug is available to everyone from private sellers or on the black market.
Last week, many media echoed a press release from the UK Regulatory Agency for Medicines and Health Products (MHRA). It called for the collaboration of people hospitalized for acute pancreatitis. The aim was to investigate whether the risk of inflammation of the pancreas in people taking GLP-1 drugs for weight loss or type 2 diabetes, such as the popular Ozempic, may be conditioned by genes. Alison Cave, responsible for safety at MHRA, estimates…
The number of people who have developed symptoms of poisoning due to incorrect use of slimming medication is increasing. This is reported by the Volkskrant based on figures from the National Poison Information Centre (NVIC). Last year, the NVIC received 75 reports of symptoms of poisoning from healthcare providers. Most people suffered from abdominal pain, nausea and vomiting. A year earlier, there were 41 reports. Last year, around 120,000 peop…
The number of people suffering from poisoning symptoms due to the incorrect use of slimming drugs is increasing rapidly. In 2024, the National...
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
